Mutant KRAS appears to be involved in over 90% of PDAC, about 50% of CRC, about 30% of NSCLC and to a lesser extent in other tumors, while mutant BRAF has primarily been observed in melanomas (3–5). This evidence concerns the gene KRAS and non-small cell lung carcinoma.